



EVITRADE Health Systems Corp Announces Operating and Joint Venture Agreement with Patent-Holder of an Excipient Carrier System for Controlled Release and Improved Solubility of Non-Soluble Materials

VANCOUVER, BC, Friday August 10, 2018 – EVITRADE Health Systems Corp. (CSE: EVA, OTCQB: AXHLF) (the “Company” or “Evitrade”) is pleased to announce that it has reached an operating and joint venture agreement with a private corporation (“PrivCo”) holding a patent for a novel excipient carrier system that allows for the controlled released and solubility of non-soluble Active Pharmaceutical Ingredients (API’s) while improving the API’s stability, shelf life and bioavailability.

“With the Company’s Operating and Joint Venture Agreement with PrivCo, we are excited of the potential of this biomaterial to positively impact the efficacy of non-soluble ingredients and protocols”, said C.K. Cheung, CEO of the Company. “While keeping our core business in the delivery of autonomous medical care, the Company is expanding its vision to include molecular biological delivery and excipient carrier systems; resulting in opportunities with potential significant revenue streams, while enhancing health outcomes and effectiveness of healthcare delivery systems”.

Privco’s patented matrix enhances the bioavailability of poorly soluble drugs and ingredients. It was originally designed to improve the performance for active pharmaceutical ingredients (API’s). The Company is looking to utilize the matrix to offer better results for food, nutraceutical and pharmaceutical protocols for Astaxanthin, Spirulina and Cannabidiol applications.

“The patented technology offers an amazing array of benefits with the potential for a low cost of manufacturing with improved solubility and bio-availability” continued C.K. “Not only does the technology improve solubility but it is 100% GRAS (Generally Recognized As Safe), reduces side effects and has the potential to extend patent protection for many near-end of life patent protocols. We are excited to be developing a program with the primary scientist that is directed at the development, production and commercialization of specific applications of the patented technology”.

Management continues to strive to seek optimal business and commercialization strategies for the Company. Due to confidentiality provisions in the current agreement, full details of the transaction will only be available upon a final definitive agreement.

Contact: C.K. Cheung, CEO & Director

EVITRADE Health Systems Corporation
(formerly Auxellence Health Corporation)

Email info@evahealthsystems.com

Website <http://www.evahealthsystems.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>

US OTC Markets: <http://www.otcm Markets.com/stock/AXHLF/news>



**EVITRADE
Health
Systems
Corporation**

About EVITRADE Health (CSE: EVA, OTCQB: AXHLF)

EVITRADE (formerly Auxellence Health Corp.), was founded in 2013 to provide online “digital healthcare” services for resolving common health problems. The current markets are weight-management, high blood pressure, high blood glucose and heart arrhythmia.

Disclaimers – Forward Looking Statements

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on www.sedar.com, <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>, and <http://www.otcmarkets.com/stock/AXHLF/filings>. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.